These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34816395)

  • 1. Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review.
    Koilakou S; Petrou P
    Mol Diagn Ther; 2021 Nov; 25(6):715-734. PubMed ID: 34816395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.
    Lange A; Prenzler A; Frank M; Kirstein M; Vogel A; von der Schulenburg JM
    Eur J Cancer; 2014 Jan; 50(1):40-9. PubMed ID: 24011538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pharmacoeconomic Analysis of Cetuximab and Panitumumab in the 1st Line Treatment of mCRC in Real Clinical Practice in the Czech Republic.
    Sehnalová I; Říhová B; Němeček R; Kintrová K; Demlová R
    Klin Onkol; 2019; 32(4):288-293. PubMed ID: 31426645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review.
    Morimoto T; Fujito K; Yamasaki B; Goto R
    Clin Ther; 2023 Jan; 45(1):41-54. PubMed ID: 36641260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
    J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
    Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
    Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
    Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil.
    da Silva WC; Godman B; de Assis Acúrcio F; Cherchiglia ML; Martin A; Maruszczyk K; Izidoro JB; Portella MA; Lana AP; Campos Neto OH; Andrade EIG
    Appl Health Econ Health Policy; 2021 Jul; 19(4):557-577. PubMed ID: 33506317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
    Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.